An observational study in Malignant External Otitis (Necrotizing/Malignant Otitis Externa) and Central Skull Base Osteomyelitis, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Communicable Diseases by Assistance Publique - Hôpitaux de Paris — 5 open to participants now, 5 under way, 1 of them phase 3. Communicable Diseases · Assistance Publique - Hôpitaux de Paris.
Among the 10 studies in Communicable Diseases by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2026, is one of 8 observational ones, and was the 10th registered.
628 studies on the registry are indexed under Communicable Diseases; 129 are open to participants now.
Browse Communicable Diseases studies →5 of the 10 studies in Communicable Diseases by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris
Ages 18+
Assistance Publique - Hôpitaux de Paris
Ages 18+
By country, each count listing its studies:
Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 100 is below the median of 200 across 229 observational studies indexed under Communicable Diseases.
Median enrollment 273 across the 2 interventional studies, 425 across the 8 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
2 of the studies in Communicable Diseases by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05903352Phase 3Assistance Publique - Hôpitaux de ParisCustomized Antibiotic Treatment Duration Among Hospitalized Patients With Moderately Severe Community-Acquired Pneumonia | 2027-05 |
| NCT06055699Assistance Publique - Hôpitaux de ParisAssociation Between the Occurrence of a Clinical RElapse and Gut MIcrobiota Modifications: a Cohort Study of Patients With pSOriasis | 2027-09-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Communicable Diseases by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Skull base osteomyelitis (SBO) is a rare and complex infection that includes malignant external otitis and central skull base osteomyelitis.
Symptoms are often non-specific, and the disease typically progresses slowly, leading to delays in diagnosis and treatment, as well as local or regional complications.
Management is not standardized and consists of medical treatment tailored to microbiological sampling results (antibiotic or antifungal therapy). Monitoring strategies and treatment modalities, particularly treatment duration, have not been standardized.
Given the rarity of these infections, it is currently very difficult to conduct prospective studies comparing different management approaches.
This will be a prospective multicenter study involving departments of Otorhinolaryngology (ENT), Infectious Diseases, Diabetology, and Internal Medicine.
Patients receiving care for skull base osteomyelitis who are seen either in outpatient consultation or during hospitalization will be included in the study, provided that their non-objection to participation has been obtained.
Patients will be managed and monitored according to standard clinical practice (routine care).
All patients aged 18 years or older diagnosed with skull base osteomyelitis (see definition below) during outpatient consultation or hospitalization at Lariboisière Hospital will be eligible for inclusion in the study, provided that they do not object to participation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Expressed refusal (objection) to participate in the study. Individuals under legal protection measures (guardianship, curatorship, or judicial protection).
Patients managed for osteoradionecrosis. Patients managed for squamous cell carcinoma of the external auditory canal.
One-year prognosis of skull base osteomyelitis
assessed by the occurrence of recurrence, relapse, and all-cause mortality within 12 months after diagnosis. Time Frame: 12 months.
Time frame: 1 year
Start is estimated for Aug 2026; primary completion for Jul 2029, 35 months later.
Of 128 non-industry observational studies under Communicable Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 77. This study's planned 35 months is close to that.
Counting every sponsor, half of 142 studies reached it within 37 months; a quarter within 17 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →